Introduction
============

Approximately 20% of colorectal cancer (CRC) cases are found to have distant metastasis at the time of diagnosis, and the 5-year survival rate is \<8%.[@b1-cmar-10-5649] The most common metastasis sites of CRC are the liver, lung, and peritoneum, but other metastatic sites have been described, such as bone, spleen, brain, and distant lymph nodes.[@b2-cmar-10-5649]--[@b4-cmar-10-5649] A nationwide retrospective review from 3,827 autopsies generated insight into the metastatic patterns and demonstrated that primary cancers tend to metastasize differently with different frequencies to distinctive sites.[@b2-cmar-10-5649],[@b4-cmar-10-5649],[@b5-cmar-10-5649] Patients with rectal cancer more often metastasize to extra-abdominal sites, whereas colon cancer patients show a higher frequency of abdominal metastasis according to the pathological records of CRC patients.[@b5-cmar-10-5649]

It is well known that the most common metastatic site for CRC patients is the liver, followed by the lung.[@b2-cmar-10-5649]--[@b4-cmar-10-5649] However, the incidence of brain metastasis (BM) is very low (1.2%--3.2%)[@b6-cmar-10-5649]--[@b9-cmar-10-5649] and is of most concern because of neurological symptoms. Additionally, CRC with BM typically occurs at a later stage of disease progression. However, data regarding BM occurrence at the diagnosis of CRC are rare.

It has been reported that cases with uncommon metastases, including BM, are increasing.[@b7-cmar-10-5649] However, the overall survival (OS) of advanced CRC has been improving due to treatment progression. Cytotoxic agents and targeted therapies have improved the prognosis of unresectable CRC patients up to 30 months.[@b10-cmar-10-5649] Currently, the advancement of immunotherapy has markedly improved the prognosis of mismatch-repair deficient (microsatellite instability-deficient) cohort of CRC.[@b11-cmar-10-5649] Multidisciplinary treatments could be applied for the treatment of metastatic lesions, including the BM.[@b12-cmar-10-5649] Therefore, early diagnosis of BM is of vital importance. Unfortunately, the risk factors associated with the initial diagnosis of BM have not yet been fully investigated due to the limited number of patients.

It has been observed in clinical trial follow-ups that mucinous adenocarcinomas (MCs) have different distribution of metastatic disease compared with the more common adenocarcinoma (AC). Right-sided colon cancer (RCC) occurs in \~10%--15% of CRC cases. RCC has often been considered a distinct entity, consisting of characteristics similar to MC with a poor prognosis in metastatic disease.[@b13-cmar-10-5649]--[@b15-cmar-10-5649] However, whether these clinical factors contribute differently to BM in CRC remains unknown.

The purpose of the present study was to use the Surveillance, Epidemiology, and End Results (SEER) database to characterize the incidence of BM at the time of CRC diagnosis and examine if BM diagnosis is a risk factor for the prognosis of CRC. In addition, we sought to examine the clinical and sociodemographic predictors of poor survival among patients with BM at CRC diagnosis.

Patients and methods
====================

Data regarding BM at the time of initial cancer diagnosis were retrieved from cases after 2010 in the SEER program of the National Cancer Institute SEER database. The data sets are available in the SEER data set repository <https://seer.cancer.gov/> and could present information on 30% of the US population.

The TNM stage was recorded as the SEER's "extent of disease" (for T and M stage) and the "number of positive nodes" (for N stage) coding schemes. Pathology was grouped as AC, MC, or other. Tumor grade was classified as well differentiated, moderately differentiated, poorly differentiated, or undifferentiated. Patients were stratified by CRC subtype, including RCC (cecum, ascending colon, hepatic flexure, and transverse colon), left-sided colon cancer (LCC; splenic flexure, descending colon, and sigmoid colon), rectosigmoid cancer (RSC; rectosigmoid junction and rectum), and appendix cancer.[@b16-cmar-10-5649] Race/ethnicity was categorized as previously described. Data on the presence of bone, lung, and liver metastases at diagnosis were available in the SEER database and were categorized as the extent of extracranial metastasis among patients in our study.

Patients were observed after their first diagnosis of CRC until the last follow-up, death, or end of the study, whichever occurred first.

Therefore, we included patients from 2010 to 2013, and patients who were proven to have BM 6 months after the diagnosis of CRC or were proven dead by autopsy were excluded. Thus, there were 170,793 patients diagnosed with CRC who were included in our analysis. Of these CRC patients, 401 were diagnosed with BM.

Statistical analysis
--------------------

Multivariable logistic regression was used to determine which characteristic was associated with the presence of BM at diagnosis among CRC patients or the M1 cohort. Multivariable Cox regression was performed to identify the covariates associated with poor survival. The Kaplan--Meier method was used to estimate the survival difference between the subgroups.

Two-sided *P\<*0.05 was considered statistically significant. Statistical analysis was performed using SAS 9.2 (SAS Institute, Cary, NC, USA).

Ethics approval and consent to participate
------------------------------------------

As the data used were from SEER data set, which is publicly available; ethics approval and consent to participate are not applicable.

Results
=======

Incidence of BM in patients diagnosed with CRC
----------------------------------------------

Among the 170,793 patients diagnosed with CRC, we demonstrated that 40.5%, 26.1%, 30.9%, and 2.5% of patients had RCC, LCC, RSC, and appendix cancer, respectively. The number and incidence of patients with CRC and identified BM at CRC diagnosis are provided in [Table 1](#t1-cmar-10-5649){ref-type="table"}, stratified by CRC cancer subtype.

Among the entire cohort, 401 patients presented with BM, reflecting 0.23% of the entire study population and 1.3% of the subset with metastatic disease at any site. Incidence proportions were highest among patients with RCC (0.2% of the entire cohort, 1.3% of the metastatic subset) and RSC (0.3% of the entire cohort, 1.5% of the metastatic subset) subtypes.

Also, 3.4% of the CRC patients with bone metastasis presented with BM at diagnosis, which was higher than that of liver or lung metastasis. Additionally, incidence proportions increased with extracranial metastatic sites (6.6% for ≥ 3, 2.2% for 2, 0.7% for 1, and 0.1% for 0). Interestingly, patients with liver metastasis demonstrated a low incidence rate (0.4%) of BM.

Multivariable logistic regression
---------------------------------

On multivariable logistic regression ([Table 2](#t2-cmar-10-5649){ref-type="table"}) among patients with metastatic cancer, T3--T4 stage patients vs Tis, T0, T1, and T2 (OR=1.456, 95% CI, 1.048--2.022, *P*=0.025), MC vs AC (OR=2.874, 95% CI, 1.385--5.967, *P*=0.005), tumor site (LCC vs RCC: OR=0.756, 95% CI, 0.581--0.983, *P*=0.037; appendix vs RCC: OR=0.151, 95% CI, 0.04--0.488, *P*=0.002), and metastatic disease to extracranial sites (bone vs none: OR=7.761, 95% CI, 5.372--11.214, *P\<*0.001; two sites vs none: OR=8.832, 95% CI, 3.484--22.386, *P*\<0.001; three vs none: OR=14.353, 95% CI, 9.311--22.125, *P\<*0.001) were associated with significantly greater odds of presenting with BM at diagnosis. Age, gender, pathology grade, N stage, tumor size, pathology grade, race, or marital status was not associated with a higher risk of BM at CRC diagnosis using the multivariable model ([Table 2](#t2-cmar-10-5649){ref-type="table"}).

Survival
========

The median survival among patients with BM (with metastasis to other organs) at diagnosis was 7.0 months ([Figure 1A](#f1-cmar-10-5649){ref-type="fig"}). As shown in [Figure 1B](#f1-cmar-10-5649){ref-type="fig"}, the median survival was 15.59 months (range 11.60--19.59 months) for patients with BM merely without metastasis to other organs ([Figure 1B](#f1-cmar-10-5649){ref-type="fig"}), which showed that patient prognosis could be improved if BM was diagnosed early. Then we compared survival difference of patients without metastasis, patients with BM only, patients with metastasis but without BM, and patients with metastasis including BM. Additionally, patients with multi-metastasis having shorter survival, and the reason maybe the BM as shown in [Figure 1B](#f1-cmar-10-5649){ref-type="fig"} (patients with metastasis without BM vs patients with metastasis including BM, *P*\<0.001).

The median survival was 9.01, 10.26, 14.57, and 5 for RCC, LCC, RSC, and appendix cancer, respectively ([Table 1](#t1-cmar-10-5649){ref-type="table"}). In the entire cohort of patients, RCC had the poorest survival and appendix cancer had the best survival (*P*\<0.001; [Figure 2A](#f2-cmar-10-5649){ref-type="fig"}). However, in patients diagnosed with BM, RCC had the best survival (*P*=0.002; [Figure 2B](#f2-cmar-10-5649){ref-type="fig"}).

The multivariable Cox regression analysis of all patients is presented in [Table 3](#t3-cmar-10-5649){ref-type="table"}. Age, T stage, N stage, pathology grade, pathology type, tumor sites, tumor size, race, marital status, extracranial metastatic number, and BM were all independent factors for poorer survival (all *P*\<0.001). Multivariable Cox regression analysis also showed that among patients with BM at CRC diagnosis, age, pathology type (MC vs AC, HR=1.146, 95% CI, 1.062--1.237, *P*\<0.001), tumor site (RSC vs RCC, HR=0.661, 95% CI, 0.491--0.890, *P*\<0.001), and extracranial metastatic number (2 vs 0/1, HR=1.471, 95% CI, 1.127--1.920, *P*\<0.001; all 3 vs 0/1, HR=1.686, 95% CI, 1.102--2.579, *P*=0.016) were significantly associated with poorer survival ([Table 3](#t3-cmar-10-5649){ref-type="table"}).

OS estimates by the extent of extracranial metastatic disease is shown is [Figure 2C, D](#f2-cmar-10-5649){ref-type="fig"}. In general, survival was poorer among patients who displayed more extensive systemic disease at CRC diagnosis. However, this trend was merely significant in the cohort of extracranial systemic disease only (3 sites vs 2 sites, *P*\<0.001; 2 sites vs 1 site, *P*\<0.001; [Figure 2E](#f2-cmar-10-5649){ref-type="fig"}) and was not found in the BM cohort (2 sites vs 1 site, *P*=0.559; 3 sites vs 2 sites, *P*=0.322; [Figure 2F](#f2-cmar-10-5649){ref-type="fig"}).

[Table 4](#t4-cmar-10-5649){ref-type="table"} displays the median survival by subtype as stratified by the extent of systemic disease in the cohort of extracranial systemic disease only and the cohort of extracranial systemic disease and BM. In addition, we found that the presence of BM at initial diagnosis was associated with a shorter survival time compared with patients who presented with de novo metastatic disease without baseline brain involvement ([Table 4](#t4-cmar-10-5649){ref-type="table"}).

Discussion
==========

In the present study, the median OS for patients with BM (with metastasis to other organs) was 7 months, which was shorter than reported previously (14.5 months).[@b17-cmar-10-5649] The median survival was 15.59 months (range 11.60--19.59 months) for patients with BM merely without metastasis to other organs. Recent studies have proved that the OS in CRC patients has improved since the late 1990s;[@b18-cmar-10-5649],[@b19-cmar-10-5649] therefore, new analyses are needed to focus on treatment for BM in patients diagnosed with CRC, especially for the patients with BM merely without metastasis to other organs.

We demonstrated that tumor site, bone metastases, and more number of extracranial metastasis were associated with BM at CRC diagnosis. Sundermeyer et al reported that lung metastasis is a risk factor for BM; the incidence is higher in lung metastasis than with liver and peritoneal metastases.[@b7-cmar-10-5649] Many studies have found that metastasis progresses sequentially in many patients, and that BM is one of the late sites of involvement.[@b20-cmar-10-5649],[@b21-cmar-10-5649] RCC showed more frequency of BM than any other tumor site among all the BM patients. Furthermore, we found that RCC was an independent risk factor of BM. Previous studies have shown that RCC may be a different entity from LCC, including differences in epidemiological, clinical, and molecular biological, and prognostic findings between RCC and LCC.[@b22-cmar-10-5649]--[@b24-cmar-10-5649] Additionally, we found that RCC had the poorest survival. However, when patients were diagnosed with BM, RCC patients had better survival than LCC patients and appendix cancer had the poorest survival. We are unsure of the mechanism of this phenomenon.

In addition, age and pathology type were independent factors in patients with BM at the diagnosis of CRC (in the whole cohort and the M1 cohort). Additionally, patients presenting with appendix tumors with BM, of age \>70 years, and with MC showed the poorest survival. Age at the time of initial diagnosis was the variable that constantly revealed a significant effect on survival, suggesting a better performance status in younger patients.[@b25-cmar-10-5649]--[@b28-cmar-10-5649] Major immune defects occur at an older age, including the lack of naïve T-cells, impaired activation pathways of T-cells, antigen-presenting cells, and age-related changes in the tumor microenvironment. Patients with MC showed poorer survival than patients with AC in CRC diagnosed with BM. The presence of metastatic disease in more than one location was more frequent in MC compared with AC.[@b5-cmar-10-5649] In MC patients, we found a high rate of peritoneal metastases. Several clinical studies have suggested differences in metastatic patterns between histological subtypes.[@b13-cmar-10-5649],[@b29-cmar-10-5649],[@b30-cmar-10-5649]

Since curative surgery is an option that is mainly limited to liver metastases, this may be an explanation for the poor performance of MC patients in trials for metastatic disease.[@b13-cmar-10-5649],[@b29-cmar-10-5649] In the current study, the unadjusted probability of BM was calculated as 3.4% for CRC metastases. The incidence of BM has increased as much as 3% since recent extended treatment options have been made available, which have caused an improvement in advanced CRC prognosis.[@b7-cmar-10-5649] Therefore, the potential of BM should be made aware to the clinicians, especially when patients present with RCC, have bone metastases, or more than three extracranial metastases. For such high-risk patients, brain scans may have to be considered.

Limitations of this study include its retrospective design, selection bias, and heterogeneous population. Furthermore, in the CRC patients, brain imaging was not routinely performed, except at the occurrence of symptoms, which may potentially underestimate the true positive rate of BM. In addition, our patients were not analyzed for the effects of gene mutation in BM tumors at the initial diagnosis, although a recent study demonstrated that RAS- or PIK3CA-mutant CRC patients were more likely to develop BM.[@b31-cmar-10-5649]

In this study we found that RCC, MC, bone metastases, and more than three extracranial metastases were independent predictors of BM in CRC patients. People with BM without metastasis to other organs had relatively better survival than BM patients with metastasis to other organs. So, it is important to improve available therapeutic options to enhance quality of life, especially for the people with BM without metastasis to other organs.
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![(**A**) Overall survival among patients with BM. (**B**) Survival stratified by subtype (nonmetastatic patients, patients with only BM, patients with metastasis to other sites but no BM, and patients with metastasis to multiple sites including BM).\
**Abbreviation:** BM, brain metastasis.](cmar-10-5649Fig1){#f1-cmar-10-5649}

![Overall survival among patients with colorectal cancer and brain metastases at diagnosis.\
**Notes:** Survival stratified by tumor site (RCC, LCC, rectosigmoid cancer, appendix cancer) (**A**) in the whole cohort or (**B**) in patients with BM. Survival stratified by the metastasis organ and the extent of extracranial metastatic disease in the (**C**) cohort of extracranial systemic disease only and the (**D**) brain metastasis cohort. Extent of extracranial metastatic disease is classified by the number of metastatic sites to the bone, lung, or liver in the (**E**) cohort of extracranial systemic disease only and (**F**) the brain metastasis cohort.\
**Abbreviations:** LCC, left-sided colon cancer; RCC, right-sided colon cancer.](cmar-10-5649Fig2){#f2-cmar-10-5649}

###### 

Incidence and median survival of patients diagnosed with CRC and identified brain metastases at diagnosis

  Subtype                       Patients (no.)   Incidence proportion of brain metastases, %   Survival among patients with brain metastases, median (IQR), months                 
  ----------------------------- ---------------- --------------------------------------------- --------------------------------------------------------------------- ------ ------ ---------------------
                                                                                                                                                                                   
  Whole cohort                  170,793          31,544                                        401                                                                   0.2%   1.3%   21.95 (21.87-22.03)
   RCC                          69,147 (40.5%)   12,451 (18.0)                                 167 (0.2%)                                                            0.2%   1.3%   9.01 (7.0-11.15)
   LCC                          44,642 (26.1%)   8,797 (19.7%)                                 92 (0.2%)                                                             0.2%   1.0%   10.26 (7.68-12.85)
  Rectosigmoid cancer           52,784 (30.9%)   9,084 (17.2%)                                 139 (0.3%)                                                            0.3%   1.5%   14.57 (11.89-17.26)
  Appendix cancer               4,220 (2.5%)     1,212 (28.7%)                                 3 (0.1%)                                                              0.1%   0.3%   5 (0.84-9.16)
  Extracranial metastasis to                                                                                                                                                       
  bone, lung, and liver (no.)                                                                                                                                                      
   0 sites                                       145,175                                       110                                                                          0.1%   15.59 (11.60-19.59)
   Bone                                          357                                           12                                                                           3.4%   10.53 (3.96-17.11)
   Lung                                          1,999                                         55                                                                           2.8%   11.66 (8.35-14.97)
   Liver                                         168,22                                        64                                                                           0.4%   10.52 (7.02-14.02)
   Two sites                                     5,400                                         121                                                                          2.2%   8.85 (7.12-10.57)
   All three sites                               540                                           39                                                                           6.6%   7.34 (4.82-9.86)

**Abbreviations:** CRC, colorectal cancer; LCC, left-sided colon cancer; RCC, right-sided colon cancer; IQR, interquartile range.

###### 

Multivariable logistic regression for the presence of brain metastases at diagnosis of colorectal cancer

  Variable                                                 Patients (no.)   Among entire cohort   Among the subset with metastatic disease                                       
  -------------------------------------------------------- ---------------- --------------------- ------------------------------------------ ----------- ----------------------- -----------
                                                                                                                                                                                 
  **Age at diagnosis (years)**                                                                                                               P\<0.001                            \<0.001
  \<40                                                     5,239            11 (0.2%)             1 (reference)                                          1 (reference)           
  40-49                                                    13,938           30 (0.2%)             1.045 (0.519-2.103)                        0.902       1.027 (0.511-2.066)     0.939
  50-59                                                    35,039           112 (0.3%)            1.634 (0.871-3.064)                        0.126       1.754 (0.936-3.285)     0.079
  60-69                                                    42,210           121 (0.3%)            1.402 (0.748-2.629)                        0.292       1.473 (0.787-2.755)     0.226
  \>70                                                     74,078           127 (0.2%)            0.853 (0.454-1.603)                        0.621       0.963 (0.514-1.805)     0.907
  **Sex**                                                                                                                                    NA                                  NA
  Male                                                     88,925           206 (0.2%)            1 (reference)                              NA          1 (reference)           NA
  Female                                                   81,467           195 (0.2%)            NA                                         NA          NA                      NA
  **T stage**                                                                                                                                **0.005**                           **0.007**
  Tis, T0, T1, T2 (0, 1, 2, 3)                             55,514           65 (0.1%)             1 (reference)                                          1 (reference)           
  T3-T4 (4, 5)                                             96,802           186 (0.2%)            1.240 (0.899-1.710                         0.189       1.456 (1.048-2.022)     0.025
  Tx                                                       18,076           150 (0.8%)            1.695 (1.224-2.347)                        0.001       1.085 (0.803-1.467)     0.594
  **N stage**                                                                                                                                0.030                               NA
  N0                                                       98,168           134 (0.1%)            1 (reference)                                          1 (reference)           NA
  N1                                                       39,027           118 (0.3%)            1.408 (1.053-1.882)                        0.021       NA                      NA
  N2                                                       21,348           76 (0.4%)             1.838 (1.202-2.811)                        0.005       NA                      NA
  Nx                                                       11,849           73 (0.6%)             1.273 (0.923-1.756)                        0.141       NA                      NA
  **Pathology grade**                                                                                                                        NA                                  0.050
  Well differentiated                                      16,648           8 (0.0%)              1 (reference)                              NA          1 (reference)           
  Moderately differentiated                                102,478          160 (0.2%)            NA                                         NA          0.581 (0.384-0.880)     0.010
  Poorly differentiated                                    23,548           100 (0.4%)            NA                                         NA          1.006 (0.635-1.596)     0.978
  Undifferentiated                                         4,588            16 (0.3%)             NA                                         NA          1.355 (0.745-2.463)     0.320
  Unknown                                                  23,130           117 (0.5%)            3.134 (1.516-6.480)                        0.002       5.149 (2.475-10.713)    \<0.001
  **Pathology type**                                                                                                                         \<0.001                             **0.005**
  Adenocarcinoma                                           151,257          339 (0.2%)            1 (reference)                                          1 (reference)           
  Mucinous carcinoma                                       13,983           27 (0.2%)             2.738 (1.336-5.613)                        0.006       2.874 (1.385-5.967)     0.005
  Other type[a](#tfn2-cmar-10-5649){ref-type="table-fn"}   3,932            22 (0.6%)             2.011 (0.968-4.176)                        0.061       1.898 (0.927-3.888)     0.089
  Unknown                                                  1,220            13 (1.1%)             4.813 (2.023-11.452)                       \<0.001     2.660 (1.119-6.323)     0.027
  **Tumor site**                                                                                                                             **0.004**                           **0.003**
  RCC                                                      68,980           167 (0.2%)            1 (reference)                                                                  
  LCC                                                      44,550           92 (0.2%)             0.766 (0.588-0.996)                        0.047       0.756 (0.581-0.983)     0.037
  Rectosigmoid                                             52,645           139 (0.3%)            0.657 (0.513-0.842)                        0.001       0.808 (0.633-1.033)     0.089
  Appendix                                                 4,217            3 (0.1%)              0.377 (0.119-1.199)                        0.098       0.151 (0.04-0.488)      0.002
  **Tumor size (mm)**                                                                                                                        NA                                  NA
  \<40                                                     69,456           81 (0.1%)             1 (reference)                              NA          1 (reference)           NA
  40-70                                                    48,304           114 (0.2%)            NA                                         NA          NA                      NA
  \>70                                                     18,304           47 (0.3%)             NA                                         NA          NA                      NA
  Unknown                                                  34,328           159 (0.5%)            NA                                         NA          NA                      NA
  **Race**                                                                                                                                   0.088                               NA
  Hispanic                                                 20,436           46 (0.2%)             1 (reference)                                          1 (reference)           NA
  Black                                                    115,273          280 (0.2%)            0.702 (0.511-0.966)                        0.030       NA                      NA
  White                                                    13,841           22 (0.2%)             1.005 (0.735-1.375)                        0.973       NA                      NA
  Asian/Pacific Islander                                   1,222            0                     0.620 (0.399-0.962)                        0.033       NA                      NA
  Native American/Alaska Native                            1,217            5 (0.4%)              1.439 (0.583-3.547)                        0.990       NA                      NA
  Unknown                                                  1,144            0                     0.000 (0.000-)                             0.990       NA                      NA
  **Marital status**                                                                                                                         NA                                  NA
  Unmarried                                                71,525           184 (0.3%)            1 (reference)                              NA          1 (reference)           NA
  Married                                                  87,779           199 (0.2%)            NA                                         NA          NA                      NA
  Unknown                                                  11,088           18 (0.2%)             NA                                         NA          NA                      NA
  **Extracranial metastasis to**                                                                                                             \<0.001                             \<0.001
  **bone, lung, and liver (no.)**                                                                                                                                                
  0 sites                                                  145,065          110 (0.1%)            1 (reference)                                          1 (reference)           
  Bone                                                     19,047           131 (0.7%)            19.212 (10.264-35.964)                     \<0.001     7.761 (5.372-11.214)    \<0.001
  Lung                                                                                            21.320 (15.045-30.212)                     \<0.001     1.306 (0.690-2.470)     0.413
  Liver                                                                                           2.572 (1.846-3.583)                        \<0.001     1.327 (0.944-1.866)     0.171
  Two sites                                                5,279            121 (2.2%)            12.780 (9.469-17.249)                      \<0.001     8.832 (3.484-22.386)    \<0.001
  All three sites                                          506              34 (6.3%)             34.847 (22.767-3.336)                      \<0.001     14.353 (9.311-22.125)   \<0.001
  Unknown                                                  495              5 (1.0%)              6.922 (2.780-17.236)                       \<0.001     1.510 (0.604-3.774)     0.377

**Note:**

The pathology type other than adenocarcinoma or mucinous carcinoma. Bold values indicate the *P* value is significant when two-sided *P*\<0.05 was considered statistically significant.

**Abbreviations:** LCC, left-sided colon cancer; NA, not available; RCC, right-sided colon cancer.

###### 

Multivariable Cox regression for overall survival among patients with brain metastases or among metastatic disease subsets

  Variable                                                 Among the subset with metastatic disease   Among the brain metastasis cohort                         
  -------------------------------------------------------- ------------------------------------------ ----------------------------------- --------------------- ---------
                                                                                                                                                                
  **Age at diagnosis (years)**                                                                        \<0.001                                                   \<0.001
  \<40                                                     1 (reference)                                                                  1 (reference)         
  40-49                                                    1.004 (0.915-1.102)                        0.928                               0.681 (0.264-1.753)   0.425
  50-59                                                    1.175 (1.078-1.280)                        \<0.001                             1.161 (0.525-2.564)   0.712
  60-69                                                    1.411 (1.297-1.535)                        \<0.001                             1.832 (0.836-4.014)   0.131
  \>70                                                     2.171 (1.997-2.359)                        \<0.001                             2.660 (1.212-5.840)   0.015
  **Sex**                                                                                             NA                                                        NA
  Male                                                     1 (reference)                                                                  1 (reference)         
  Female                                                   NA                                         NA                                  NA                    NA
  **T stage**                                                                                         \<0.001                                                   NA
  Tis, T0, Tl, T2 (0, 1, 2, 3)                             1 (reference)                                                                  1 (reference)         
  T3-T4 (4, 5)                                             1.018 (0.970-1.069)                        0.469                               NA                    NA
  Tx                                                       1.099 (1.048-1.153)                        \<0.001                             NA                    NA
  **N stage**                                                                                         \<0.001                                                   NA
  N0                                                       1 (reference)                                                                  1 (reference)         
  N1                                                       0.926 (0.887-0.967)                        0.001                               NA                    NA
  N2                                                       1.090 (1.028-1.155)                        0.004                               NA                    NA
  Nx                                                       1.082 (1.032-1.134)                        0.001                               NA                    NA
  **Pathology grade**                                                                                 \<0.001                                                   NA
  Well differentiated                                      1 (reference)                                                                  1 (reference)         
  Moderately differentiated                                1.723 (1.591-1.865)                        \<0.001                             NA                    NA
  Poorly differentiated                                    1.845 (1.668-2.041)                        \<0.001                             NA                    NA
  Undifferentiated                                         2.577 (0.858-7.740)                        0.092                               NA                    NA
  Unknown                                                  1.584 (0.605-4.146)                        0.349                               NA                    NA
  **Pathology type**                                                                                  \<0.001                                                   \<0.001
  Adenocarcinoma                                           1 (reference)                                                                  1 (reference)         
  Mucinous carcinoma                                       1.102 (1.048-1.159)                        \<0.001                             1.146 (1.062-1.237)   \<0.001
  Other type[a](#tfn4-cmar-10-5649){ref-type="table-fn"}   1.613 (1.512-1.721)                        \<0.001                             0.883 (0.337-2.315)   0.800
  Unknown                                                  2.269 (2.083-2.471)                        \<0.001                             1.185 (0.450-3.123)   0.731
  **Tumor site**                                                                                      \<0.001                                                   0.029
  RCC                                                      1 (reference)                                                                  1 (reference)         
  LCC                                                      0.813 (0.786-0.842)                        \<0.001                             0.984 (0.722-1.342)   0.919
  Rectosigmoid                                             0.654 (0.631-0.679)                        \<0.001                             0.661 (0.491-0.890)   0.006
  Appendix                                                 0.423 (0.381-0.470)                        \<0.001                             0.372 (0.047-2.970)   0.351
  **Tumor size**                                                                                      \<0.001                                                   NA
  \<40                                                     1 (reference)                                                                  1 (reference)         
  40-70                                                    1.122 (1.077-1.168)                        \<0.001                             NA                    NA
  \>70                                                     1.278 (1.218-1.342)                        \<0.001                             NA                    NA
  Unknown                                                  1.182 (1.131-1.235)                        \<0.001                             NA                    NA
  **Race**                                                                                            \<0.001                                                   NA
  Hispanic                                                 1 (reference)                                                                  1 (reference)         
  Black                                                    1.117 (1.073-1.163)                        \<0.001                             NA                    NA
  White                                                    1.013 (0.966-1.061)                        0.599                               NA                    NA
  Asian/Pacific Islander                                   0.946 (0.896-1.000)                        0.050                               NA                    NA
  Native American/Alaska Native                            1.273 (1.086-1.491)                        0.003                               NA                    NA
  Unknown                                                  0.712 (0.459-1.105)                        0.130                               NA                    NA
  **Marital status**                                                                                  \<0.001                             NA                    NA
  Unmarried                                                1 (reference)                                                                  NA                    NA
  Married                                                  0.802 (0.779-0.826)                        \<0.001                             NA                    NA
  Unknown                                                  0.849 (0.796-0.907)                        \<0.001                             NA                    NA
  **Extracranial metastasis to bone,**                                                                \<0.001                                                   0.004
  **lung, and liver (no.)**                                                                                                                                     
  0/1                                                      1 (reference)                                                                                        
  2                                                        1.109 (1.066-1.153)                        \<0.001                             1.471 (1.127-1.920)   0.004
  All three                                                1.423 (1.356-1.494)                        \<0.001                             1.686 (1.102-2.579)   0.016
  Unknown                                                  1.854 (1.673-2.054)                        \<0.001                                                   
  Brain metastasis (yes vs no)                             1.360 (1.203-1.536)                        \<0.001                                                   

**Note:**

The pathology type other than adenocarcinoma or mucinous carcinoma.

**Abbreviations:** LCC, left-sided colon cancer; NA, not available; RCC, right-sided colon cancer.

###### 

Median survival of colorectal cancer patients by the extent of systemic metastatic disease

  Subtype                                                                              Survival, median, months   
  ------------------------------------------------------------------------------------ -------------------------- --------------------
                                                                                                                  
  **Extracranial metastasis to bone, lung, and liver or number of metastasis sites**                              
  Bone                                                                                 23.91 (22.81-25.01)        10.53 (3.96-17.11)
  Lung                                                                                 14.36 (13.86-14.86)        10.52 (7.02-14.02)
  Liver                                                                                21.21 (20.86-21.57)        11.66 (8.35-14.97)
  Two sites                                                                            13.93 (11.76-16.10)        8.85 (7.13-10.97)
  All three sites                                                                      9.51 (8.41-10.62)          7.34 (4.82-9.86)
